Diabetic Ketoacidosis (DKA) is traditionally characterized by the triad of hyperglycemia, metabolic acidosis, and ketoacidosis. However, approximately 3% of DKA cases are caused by Euglycemic DKA (EDKA). In the past, this percentage was significantly lower, but the...
A few months back, I compared one of the newest SGLT2 inhibitors in bexagliflozin to the other agents in this class of medication. To sum up my analysis, bexagliflozin provided nothing significantly different from the other SGLT2 inhibitors. In fact, it has less...
As a geriatric pharmacist, I’m always on high alert for the prescribing cascade. I outline my top 5 examples of the prescribing cascade in diabetes care in this article. Metformin and Loperamide Metformin has been the go-to first-line agent of choice for years....
A new SGLT2i is now on the market, promoting a new option for diabetes management. Bexagliflozin (Brenzavvy) got FDA approval in January of this year adding it to the list of SGLT2 inhibitors. With a few already on the scene, it bears the question, is bexagliflozin...
The American Diabetes Association released their 2022 Diabetes Guidelines update. While I wouldn’t call the changes earth-shattering, there are some items in relation to pharmacotherapy that I feel are really important to note. The patient population that I work...
